Tema Etfs LLC Buys New Shares in Celldex Therapeutics, Inc. (NASDAQ:CLDX)

Tema Etfs LLC bought a new position in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 29,480 shares of the biopharmaceutical company's stock, valued at approximately $745,000.

Other institutional investors and hedge funds have also recently made changes to their positions in the company. Deep Track Capital LP bought a new position in Celldex Therapeutics during the 4th quarter worth $38,919,000. Point72 Asset Management L.P. grew its holdings in shares of Celldex Therapeutics by 50.8% during the 4th quarter. Point72 Asset Management L.P. now owns 2,515,972 shares of the biopharmaceutical company's stock worth $63,579,000 after purchasing an additional 847,264 shares in the last quarter. Price T Rowe Associates Inc. MD increased its position in shares of Celldex Therapeutics by 23.5% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 3,557,136 shares of the biopharmaceutical company's stock worth $89,890,000 after purchasing an additional 676,771 shares during the period. American Century Companies Inc. increased its position in shares of Celldex Therapeutics by 46.5% in the fourth quarter. American Century Companies Inc. now owns 608,457 shares of the biopharmaceutical company's stock worth $15,376,000 after purchasing an additional 193,093 shares during the period. Finally, TFG Asset Management GP Ltd acquired a new position in Celldex Therapeutics in the fourth quarter valued at about $4,852,000.

Celldex Therapeutics Stock Down 2.6%

Shares of CLDX stock traded down $0.54 during trading hours on Wednesday, hitting $19.95. 1,329,886 shares of the company's stock traded hands, compared to its average volume of 897,252. The stock has a market cap of $1.32 billion, a PE ratio of -7.76 and a beta of 1.39. Celldex Therapeutics, Inc. has a 12 month low of $14.40 and a 12 month high of $47.00. The stock's 50 day simple moving average is $18.91 and its 200 day simple moving average is $22.51.

Celldex Therapeutics (NASDAQ:CLDX - Get Free Report) last posted its quarterly earnings data on Thursday, May 8th. The biopharmaceutical company reported ($0.81) EPS for the quarter, missing analysts' consensus estimates of ($0.75) by ($0.06). Celldex Therapeutics had a negative net margin of 1,544.32% and a negative return on equity of 19.75%. The firm had revenue of $0.70 million during the quarter, compared to the consensus estimate of $1.08 million. As a group, equities research analysts expect that Celldex Therapeutics, Inc. will post -2.48 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

CLDX has been the topic of a number of analyst reports. HC Wainwright reiterated a "buy" rating and set a $80.00 price objective on shares of Celldex Therapeutics in a research note on Tuesday, May 6th. The Goldman Sachs Group cut their price target on shares of Celldex Therapeutics from $36.00 to $31.00 and set a "neutral" rating for the company in a report on Friday, May 9th. Canaccord Genuity Group assumed coverage on shares of Celldex Therapeutics in a research note on Monday, April 28th. They issued a "buy" rating and a $64.00 price objective on the stock. Cantor Fitzgerald reissued an "overweight" rating and set a $67.00 target price on shares of Celldex Therapeutics in a research note on Wednesday, January 29th. Finally, Morgan Stanley dropped their price target on Celldex Therapeutics from $46.00 to $43.00 and set an "overweight" rating for the company in a research note on Friday, May 9th. Two investment analysts have rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $53.90.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.